Showing 1881-1890 of 3038 results for "".
- Genentech Initiates Phase 3 Trial for Port Delivery System with Ranibizumab in Diabetic Retinopathyhttps://modernod.com/news/late-stage-trial-starts-for-port-delivery-system-with-ranibizumab-in-diabetic-retinopathy/2478224/Genentech has initiated a new phase 3 clinical trial investigating Port Delivery System with ranibizumab (PDS) for people with diabetic retinopathy (DR). PDS is a permanent refillable eye implant, approximately the size of a grain of rice, which continuously delivers a customized formulation of r
- Serum Institute to Produce COVID-19 Vaccines From AstraZeneca, Novavaxhttps://modernod.com/news/serum-institute-to-produce-covid-19-vaccines-from-astrazeneca-novavax/2478139/The Serum Institute of India (SII) said it will produce coronavirus vaccines from AstraZeneca and Novavax, making them available for procurement, if they gain marketing approval, at a ceiling price of $3 per dose. SII noted that it will use funding from Gavi, The Vaccine Alliance and the Bill &am
- Novavax Reports Positive Early Results for Experimental COVID-19 Vaccine NVX-CoV2373https://modernod.com/news/novavax-reports-positive-early-results-for-experimental-covid-19-vaccine-nvx-cov2373/2478122/Novavax announced preliminary data from a phase 1/2 study indicating that its recombinant coronavirus vaccine candidate NVX-CoV2373 triggered immune responses in healthy adults and was generally well-tolerated. According to findings in a paper, Novavax submitted to the preprint server medRxiv, th
- New Licensing Agreement Accelerates the Development of IACTA Pharmaceuticals’ Novel Dry Eye Disease and Allergic Conjunctivitis Treatments in China and Southeast Asiahttps://modernod.com/news/new-licensing-agreement-accelerates-the-development-of-iacta-pharmaceuticals-novel-dry-eye-disease-and-allergic-conjunctivitis-treatments-in-china-and-southeast-asia/2478088/IACTA Pharmaceuticals and Zhaoke Ophthalmology Pharmaceutical (ZKO), a Hong Kong-based pharmaceutical company, announced they have entered into a definitive license agreement on the licensing of two of the company’s products, IC 265 for dry eye and IC 270 fo
- New Novartis Analysis Examines Sustainable Fluid Control of Beovu Compared With Aflibercepthttps://modernod.com/news/new-novartis-analysis-shows-wet-amd-patients-achieved-sustained-fluid-control-faster-with-beovu-versus-aflibercept/2478080/Novartis announced results of a new post-hoc analysis of Beovu (brolucizumab) phase 3 HAWK and HARRIER pivotal trials demonstrating faster sustainable fluid control when compared with aflibercept in patients with wet
- Novartis Launches “Not Today, Dry Eye” Consumer Campaignhttps://modernod.com/news/novartis-launches-not-today-dry-eye-consumer-campaign/2478073/This month, Novartis launched its new direct-to-consumer commercial and campaign “Not Today, Dry Eye,” which aims to improve awareness of dry eye disease (DED) among consumers. This campaign underscores the fact that inflammation can play an important role in the development and amplification of
- Phase 3 Data Show Port Delivery System With Ranibizumab Enabled Over 98% of Patients to Go 6 Months Between Treatments for Wet AMDhttps://modernod.com/news/phase-3-data-show-port-delivery-system-with-ranibizumab-enabled-over-98-of-patients-to-go-6-months-between-treatments-for-wet-amd/2478061/Genentech announced detailed results from the phase 3 Archway study evaluating its investigational Port Delivery System with ranibizumab (PDS) for the treatment of wet age-related macular degeneration (AMD). In Archway, 98.4% of PDS patients were able to go 6 months without needing additio
- Norlase Announces CE Mark Approval for LEAF Green Laserhttps://modernod.com/news/norlase-announces-ce-mark-approval-for-leaf-green-laser/2478045/Norlase announced that it has been granted the CE Mark approval for the LEAF, a first in class, fiberless green laser for the treatment of retina and glaucoma diseases. The CE Mark follows the recent FDA 510(k) market clearance of the LEAF and ISO 13485:2016 certification of Norlase’s medical dev
- Novartis to Provide 15 Drugs at Zero-Profit for Treating COVID-19 Symptomshttps://modernod.com/news/novartis-to-provide-15-drugs-at-zero-profit-for-treating-covid-19-symptoms/2478027/Novartis announced Thursday that 15 generic and over-the-counter medicines from its Sandoz unit will be made available at zero-profit to treat the major symptoms of COVID-19 in low-income and lower-middle-income countries. The drugs include those to treat gastro-intestinal illness, acute respirat
- Novavax Gains $1.6 Billion in Funding for COVID-19 Vaccine Candidatehttps://modernod.com/news/novavax-gains-1-6-billion-in-funding-for-covid-19-vaccine-candidate/2477984/Novavax announced that it has been awarded $1.6 billion by the US government to progress development of NVX CoV2373 and potentially deliver 100 million doses of the COVID-19 vaccine as early as late 2020. NVX‑CoV2373 consists of a stable, prefusion protein made using Novavax’s nanop